Drug Discovery World

DECEMBER 27, 2023

Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Listen here. Listen here. Listen here. This episode is available here.

Clinical Trials 69

Clinical Trials Clinical Trials Drugs Development 69

pharmaphorum

AUGUST 31, 2021

ECAs are being used to support the primary approval, label expansion of their assets and even go/no-go decisions for trials. For the innovators and early adopters of the life sciences industry, engineering a regulatory-grade ECA can be daunting. Myth 1: There are too many challenges with adopting an ECA.

Clinical Trials 82

Clinical Trials Clinical Trials Life Science Trials 82

Drug Discovery World

FEBRUARY 6, 2024

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. The company’s platform evaluated more than 11.4

Marketing 69

Marketing Medicine Genome Genomics 69

Placebo Control

MAY 30, 2013

Even by the already-painfully-embarrassingly-low standards of clinical trial enrollment in general, patient enrollment in cancer clinical trials is slow. In many cancer trials, randomizing one patient every three or four months isn't bad at all – in fact, it's par for the course. Horribly slow.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Pharma Companies 40

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. cells, receptors) to treat disease.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

JANUARY 29, 2021

Since that discovery, a flurry of gene-editing focused biopharma companies have launched – including Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences and Mammoth Biosciences – and the first drug therapies based on the technology are now in human testing for diseases like cancer. billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Drug Discovery World

JANUARY 21, 2024

He will also explain the importance of this innovation as a way to mitigate the high failure rates in clinical trials, which historically see 92% of drugs fail despite passing animal tests, leading to significant financial and time losses in the industry (approximately $53 billion for pharma companies annually).

Protein 52

Protein Vaccination Vaccine Development 52

pharmaphorum

APRIL 26, 2022

At the same time, the pharma industry has also started to note the potential for a new treatment paradigm to be developed, and investment into the space has started to increase. In the trial, Seres announced that the product candidate had met its primary endpoint, showing a statistically significant 30.2% difficile infection (CDI).

Containment 113

Containment Development Production Immune Response 113

pharmaphorum

FEBRUARY 11, 2022

Sun says because of this, Komodo engineered solutions or apps that “do certain things for end-users applied against the Healthcare Map.”. This technology can be particularly beneficial for rare disease organisations as they often don’t have data scientists at their disposal or full-stack engineers.

Life Science 103

Life Science Engineer Development Big Data 103

Drug Discovery World

JULY 18, 2022

Troy Groetken of intellectual property and technology law firm McAndrews, Held & Malloy tells Lu Rahman how pharma companies can take this data from where it currently stands (drug design and development) to a more clinical level. Investment will be significant and ongoing for companies who wish to develop within this arena.

Big Data 52

Big Data Life Science Development Clinical Trials 52

Drug Discovery World

OCTOBER 4, 2022

The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. . billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

OCTOBER 26, 2022

For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. Chiesi’s approach to these trials presents a clear demonstration of Chiesi’s patient-centricity approach in action. Caring for a global community.

Development 95

Development Trials Marketing Life Science 95

pharmaphorum

MARCH 28, 2022

Built under a government tender, AION Labs comprises four large international pharma companies – AstraZeneca , Merck, Pfizer , and Teva – and another core partner, the Israel Biotech Fund. At times, companies invest millions of dollars in developing and studying a therapy that may find to be ineffective. The partnership.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Placebo Control

JANUARY 12, 2014

In it, Roger Stein claims to have created an approach to advancing drugs through clinical trials that will "fundamentally change the way research for cancer and lots of other things gets done". However, they definitely think this is qualitatively different from existing pharma companies, and offer a couple reasons.

Development 40

Development Drugs Pharma Companies Engineer 40

Drug Discovery World

NOVEMBER 16, 2022

On the point of consistency, the fact that organoids are a relatively new technology means that there isn’t a set ‘baseline’ in how companies grow them, with the differentiation potentially affecting research undertaken with them. “One One of the biggest pain points is really the consistency of organoids.

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

pharmaphorum

APRIL 1, 2021

In the past couple of years, Turbine worked with a number of big pharma companies, including Bayer, and has also started building its own pipeline, including a target delivering new biological insight in PARP inhibitor resistance. “We That’s an area that we’re also looking at launching collaborations in.

Bioinformatics 113

Bioinformatics Drugs Development Scientist 113

Drug Discovery World

OCTOBER 16, 2023

Despite the overall reduction in major pharma R&D centres in the UK, global pharma companies continue to engage with academic and biotech organisations here, particularly in hotspots such as the Golden Triangle, the Northwest, and Scotland, through the strong networks that have been developed between these organisations.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

OCTOBER 25, 2023

JV: A key bottleneck in the research and development of a drug is the lengthy experimentation that is required to gain the confidence to run clinical trials. JV: Our mission is to solve the translational challenges that every biotech and pharma company faces, and get more novel therapies to patients, faster.

Drugs 111

Drugs Pharma Companies Clinical Trials Clinical Trials 111

XTalks

JULY 10, 2023

This is not a side project for our engineers or the IT team. I hope we can replicate this with many other pharma companies; that’s the goal for us. Kaushik Gune: I think that the answer lies in Huma’s company history. How do you address cybersecurity in your platform? Number one is investment.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

pharmaphorum

NOVEMBER 3, 2022

As we strive to improve the medical product development process and speed the development of effective new therapies to patients, digital health solutions are becoming increasingly available, affordable, and anticipated in healthcare settings by patients, clinicians, and caregivers alike, driving expectations for trial participants.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Medicine 80

pharmaphorum

NOVEMBER 1, 2021

Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in August at 1.43 million yen (around $12,500) per dose, according to a Pharma Japan report.

Genetic Engineering 120

Genetic Engineering Clinical Trials Clinical Trials Trials 120

XTalks

DECEMBER 20, 2023

This includes analyzing how drug combinations may impact individual patients or groups of patients before even entering a clinical trial. With a staggering 90 percent of drugs failing in clinical trials, AI has the potential to help improve these statistics. These companies are at various stages of research and clinical trials.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

pharmaphorum

JUNE 14, 2021

The green light in Japan is based on data from a single-arm phase 2 clinical trial, which showed that Delytact boosted the one-year survival rate in patients with residual or recurrent glioblastoma who had been treated with radiotherapy and temozolomide chemotherapy and had one residual tumour or one recurrent lesion.

Clinical Trials 117

Clinical Trials Clinical Trials Trials Pharma Companies 117

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. million and $38.8 million, respectively, as compared to $17.6

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

AUGUST 9, 2022

The potential of the area has motivated an increasing number of companies to emerge in the space, with a greater number of collaborations occurring between these AI-specialists and big pharma companies. To develop this particular candidate, the company designed and eliminated 175 novel candidates. Patient focus.

Drugs 108

Drugs Doctors Doctor Pharma Companies 108

Drug Discovery World

JANUARY 26, 2023

As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% in 2022, a steep decline compared to the record 6.8% the industry experienced in 2021.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

MAY 24, 2022

Pharma companies hold masses of vital data sets, from classified intellectual property to proprietary information about drugs and clinical trial developments. This was illustrated in 2021, amid growing awareness of the pharma industries’ efforts to develop and distribute COVID-19 vaccines.

Pharma Companies 145

Pharma Companies Development Engineer Clinical Trials 145

XTalks

NOVEMBER 16, 2021

Fischer, 54, of Hopatcong, NJ was the only other passenger on board the single-engine Cessna 172 aircraft, and also did not survive the crash. Medidata co-founder Glen M. de Vries, 49, was killed after the plane he was traveling on crashed in a wooded area in Hampton, New Jersey on November 11.

Life Science 98

Life Science Clinical Research Pharma Companies Engineer 98

Drug Discovery World

MAY 29, 2024

The project will combine Oxford’s academic research capabilities with SpyBiotech’s proprietary SPYVLP platform technology to advance three vaccine candidates targeting EBV and test these in a Phase I clinical trial. We see a great need for a vaccine against EBV.”

Drugs 52

Drugs Gene Editing Life Science Genome 52

Drug Discovery World

OCTOBER 7, 2022

Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. TH : Cancer Research Horizons is the new innovation engine from Cancer Research UK. Tony Hickson.

HR 52

HR Research Drugs Development 52

Delveinsight

FEBRUARY 12, 2021

This is set to change in the upcoming future as several companies, including GlaxoSmithKline , Adaptimmune , Advenchen Laboratories , intend to bring revolutionary therapies in the market for Synovial sarcoma. Advenchen Laboratories is running a global Phase III trial of its candidate, AL3818 (Anlotinib) for Synovial sarcoma.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

XTalks

OCTOBER 1, 2020

The drug is currently in clinical trials for alcoholic hepatitis (AH), nonalcoholic steatohepatitis (NASH), as well as in COVID-19 patients with acute liver or kidney injury. The ability to recruit the right people, especially in terms of data science and software engineers, [is there]. Key Moments. Focus Fueling Pace.

Scientist 52

Scientist In-Vitro Research Life Science 52

Pharmaceutical Technology

JUNE 22, 2023

Data exclusivity has been a heated point of debate in the recently announced pharmaceutical reform, which aims to shorten it from eight years to six, drawing the ire of pharma companies. The EC has said there will be a 15-year testing period wherein the scheme will be trialed.

Drugs 130

Drugs Development Pharma Companies Marketing 130

World of DTC Marketing

AUGUST 16, 2021

On average, citizens of other rich countries spend 56 percent of what Americans spend on the same drug” PhRMA, of course, will counter this push by saying that drug companies need the money for R&D even though they used the recent Trump tax cuts to buy back stock and reward shareholders. Leading lobbying industries in the U.S.

Drugs 180

Drugs Pharma Companies Engineer Clinical Trials 180